Antimicrobial showed no clear difference in systemic UTI compared with placebo or no antibiotics (low certainty).
Antimicrobial may leads to lower symptomatic UTI compared with placebo or no antibiotics (low certainty).
It is very uncertain whether antimicrobial changes serious adverse events compared with placebo or no antibiotics (very low certainty).
Antimicrobial showed no clear difference in minor adverse events compared with placebo or no antibiotics (low certainty).
It is very uncertain whether antimicrobial changes localized UTI compared with placebo or no antibiotics (very low certainty).
It is very uncertain whether antimicrobial changes bacterial resistance compared with placebo or no antibiotics (very low certainty).
It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with ciprofloxacin (very low certainty).
It is very uncertain whether ciprofloxacin changes clinical efficacy ‐ cure or improvement at end of treatment compared with comparator fluoroquinolone (very low certainty).
Ciprofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with comparator fluoroquinolone (very low certainty).
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
Levofloxacin showed no clear difference in clinical efficacy ‐ cure or improvement at end of treatment compared with ciprofloxacin (low certainty).
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with ciprofloxacin (moderate certainty).
Lomefloxacin showed no clear difference in microbiological efficacy ‐ pathogen eradication at compared with comparator fluoroquinolone (low certainty).
Lomefloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
It is very uncertain whether ciprofloxacin changes microbiological efficacy ‐ pathogen eradication at end of treatment compared with comparator fluoroquinolone (very low certainty).